|
Tue, 12/13/2022 - 10:51 |
Next-Generation Drug Improves Progression-Free Survival in Relapsed Chronic Lymphocytic Leukemia |
Dana Farber |
|
Tue, 07/12/2022 - 08:16 |
FDA Warns Four Companies for Selling Tainted Honey-based Products with Hidden Active Drug Ingredients |
FDA |
|
Mon, 12/06/2021 - 11:04 |
Drug used to treat erectile dysfunction may have potential for Alzheimers |
Alzheimers Research |
|
Thu, 01/23/2020 - 14:38 |
Pfizers Greenstone and Digital Mens Health Clinic Roman Collaborate to Offer Patients Remote Access to the Only FDA-Approved Authorized Generic Version of Viagra (sildenafil citrate) |
Pfizer |
|
Sun, 12/02/2018 - 12:52 |
Celgene Corporation Announces Initial Phase 1/2 Liso-cel Data in Patients with Relapsed/Refractory CLL, Including Those with High-Risk Disease, Previously Treated with Ibrutinib, at ASH 2018 |
BMS |
|
Mon, 10/15/2018 - 07:45 |
Dietary Supplements Work (When You Add a Real Drug to Them) |
American Counci... |
|
Mon, 12/11/2017 - 08:18 |
Teva Announces Exclusive Launch of Generic Viagra Tablets in the United States |
Teva Pharmaceutical |
|
Mon, 12/04/2017 - 21:37 |
Phase 3 Study Evaluating IMBRUVICA (ibrutinib) in Combination with Rituximab in Waldenstroms Macroglobulinemia Met Primary Endpoint |
Johnson and Johnson |
|
Wed, 08/02/2017 - 12:11 |
The approval provides an important new treatment option for adults living with debilitating and potentially life-threatening condition |
Johnson and Johnson |
|
Fri, 06/23/2017 - 11:30 |
ArQule Presents Preclinical Data for BTK Inhibitor, ARQ 531, at the 22nd Annual Congress of the European Hematology Association (EHA) |
ArQule |
|
Thu, 06/15/2017 - 18:39 |
Feinstein Institute Scientist Recognized for Innovative Chronic Lymphocytic Leukemia Research |
Feinstein Institute |
|
Thu, 05/18/2017 - 04:12 |
ArQule to Present Preclinical Data for BTK Inhibitor, ARQ 531, at the 22nd Annual Congress of the European Hematology Association (EHA) |
ArQule |
|
Tue, 04/04/2017 - 05:09 |
GVHD is a life-threatening condition with limited treatment options |
Johnson and Johnson |
|
Thu, 01/19/2017 - 06:43 |
IMBRUVICA (ibrutinib) Approved by FDA for Marginal Zone Lymphoma (MZL) Patients Who Require Systemic Therapy and Have Received At Least One Prior Anti-CD20-Based Therapy |
Johnson and Johnson |
|
Tue, 12/06/2016 - 10:47 |
Data at the American Society of Hematology Annual Meeting highlight potential role of ibrutinib therapy beyond hematologic cancers |
Johnson and Johnson |
|
Mon, 12/05/2016 - 12:02 |
New Ibrutinib (IMBRUVICA) Phase 2 Data Demonstrate Promise in Relapsed/Refractory Marginal Zone Lymphoma (MZL), a Rare, Incurable Type of Non-Hodgkins Lymphoma |
Johnson and Johnson |
|
Mon, 07/18/2016 - 21:33 |
ArQule Presents Preclinical Data for ARQ 531, a Proprietary Reversible Inhibitor of Wild Type and Mutant BTK, at the 2016 Pan Pacific Lymphoma Conference |
ArQule |
|
Fri, 05/13/2016 - 03:48 |
Erectile Dysfunction (ED) Drugs Market to Decline at 4.50% CAGR till 2019 due to Patent Expiration of Blockbuster Drugs |
transparencymar... |
|
Fri, 06/26/2015 - 13:10 |
Erectile dysfunction drugs and skin cancer |
AAD |
